An Open-Label, Single-Arm, Multicenter, Phase II Trial of Bireociclib As Monotherapy for Heavily Pretreated HR-positive, HER2-negative Advanced Breast Cancer Patients: BRIGHT-1 Trial.
Cancer communications (London, England)（2025）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要